Edition:
United States

Sanofi SA (SNY.N)

SNY.N on New York Stock Exchange

42.76USD
21 Feb 2017
Change (% chg)

$-0.40 (-0.93%)
Prev Close
$43.16
Open
$42.18
Day's High
$42.77
Day's Low
$42.08
Volume
336,012
Avg. Vol
254,036
52-wk High
$44.50
52-wk Low
$36.82

SNY.N

Chart for SNY.N

About

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $109,258.80
Shares Outstanding(Mil.): 2,584.04
Dividend: 1.58
Yield (%): 3.71

Financials

  SNY.N Industry Sector
P/E (TTM): 23.59 28.81 29.68
EPS (TTM): 1.80 -- --
ROI: 5.02 13.56 13.06
ROE: 7.60 14.44 14.19

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.

Feb 16 2017

UPDATE 2-How Sanofi lost out to J&J in $30 bln battle for Actelion

* J&J's $280 per share tender offer to start March 3 (Recasts with rival offer, adds background throughout)

Feb 16 2017

Deals of the day-Mergers and acquisitions

Feb 13 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

Feb 13 2017

BRIEF-Ipsen acquires a portfolio of select consumer healthcare products from Sanofi

* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi

Feb 13 2017

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

Feb 13 2017

UPDATE 1-Drugmaker Ipsen to buy some products from Sanofi for 83 mln euros

PARIS, Feb 13 Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.

Feb 13 2017

Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg

Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.

Feb 12 2017

BRIEF-Sanofi nearing deal to sell some over-the-counter products to Ipsen for about 100 mln euros- Bloomberg, citing source

* Sanofi nearing agreement to sell some over-the-counter products to Ipsen; deal may be announced as soon as Monday- Bloomberg, citing source

Feb 12 2017

Regeneron pins hope on eczema drug as Eylea sales slow

Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.

Feb 09 2017

UPDATE 3-Regeneron pins hope on eczema drug as Eylea sales slow

* Shares rise as much as 4 pct (Adds conference call details; updates shares)

Feb 09 2017

More From Around the Web

Earnings vs. Estimates